- Home
- AMGN vs BKNG Comparison
AMGN vs BKNG Comparison
Compare AMGN & BKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- BKNG
- Stock Information
- Founded
- AMGN 1980
- BKNG 1997
- Country
- AMGN United States
- BKNG United States
- Employees
- AMGN N/A
- BKNG N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- BKNG Transportation Services
- Sector
- AMGN Health Care
- BKNG Consumer Discretionary
- Exchange
- AMGN Nasdaq
- BKNG Nasdaq
- Market Cap
- AMGN 152.1B
- BKNG 163.6B
- IPO Year
- AMGN N/A
- BKNG 1999
- Fundamental
- Price
- AMGN $277.49
- BKNG $4,993.80
- Analyst Decision
- AMGN Buy
- BKNG Buy
- Analyst Count
- AMGN 22
- BKNG 34
- Target Price
- AMGN $334.58
- BKNG $4,708.87
- AVG Volume (30 Days)
- AMGN 2.5M
- BKNG 256.3K
- Earning Date
- AMGN 10-30-2024
- BKNG 10-30-2024
- Dividend Yield
- AMGN 3.23%
- BKNG 0.70%
- EPS Growth
- AMGN N/A
- BKNG 2.91
- EPS
- AMGN 7.83
- BKNG 145.91
- Revenue
- AMGN $32,534,000,000.00
- BKNG $23,052,000,000.00
- Revenue This Year
- AMGN $20.06
- BKNG $11.95
- Revenue Next Year
- AMGN $3.50
- BKNG $8.67
- P/E Ratio
- AMGN $35.59
- BKNG $34.39
- Revenue Growth
- AMGN 21.25
- BKNG 11.74
- 52 Week Low
- AMGN $260.52
- BKNG $3,079.50
- 52 Week High
- AMGN $346.85
- BKNG $5,069.44
- Technical
- Relative Strength Index (RSI)
- AMGN 22.11
- BKNG 75.59
- Support Level
- AMGN $293.80
- BKNG $4,913.04
- Resistance Level
- AMGN $328.25
- BKNG $5,069.44
- Average True Range (ATR)
- AMGN 8.26
- BKNG 98.79
- MACD
- AMGN -4.08
- BKNG 5.36
- Stochastic Oscillator
- AMGN 4.26
- BKNG 92.45
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About BKNG Booking Holdings Inc.
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.